Skip to content

Hemab Therapeutics Holdings

US · COAG #3007 by market cap Listed 2026
39.29 -0.57 -1.43%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 24 in the most recent period (2026/Q3).
  • Total institutional ownership rose 6.8 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
107.40% +6.85pp
Institutions
87 +24
As of
2026/Q3 vs. prior period

Holder types

VC/PE Fund61.82%
Mutual Fund32.35%
Hedge Fund12.68%
Individual/Insider0.26%
Public Company0.23%
Endowment Fund0.21%

Top holders as of 2026-06-30

RA Capital Management, L.P. 16.71% · 7.81M sh
Access Biotechnology 10.44% · 4.88M sh
FMR 10.43% · 4.87M sh
Novo Holdings A/S 8.95% · 4.18M sh
Deep Track Capital, LP 7.71% · 3.60M sh
Capital Research 7.71% · 3.60M sh
Avoro Capital Advisors LLC 7.06% · 3.30M sh
Sofinnova Partners SAS 5.37% · 2.51M sh
Artal Group S.A. 5.06% · 2.37M sh
Odlander, Fredrikson & Co. AB 4.05% · 1.89M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

29 filings tracked · 15 buys · 0 sells

NameRoleStake
RA Capital Management, L.P. -- 16.71%
Access Biotechnology -- 10.44%
Mads Behrndt-Eriksen CFO & GM 0.19%
John Michael Maraganore Independent Chairperson 0.08%
Novo Holdings A/S -- --
Akshay Vaishnaw Independent Director --
Linda Bain Independent Director --
Benny Sorensen Chief Executive Officer --
Keli Walbert Director --
Catherine Madigan Chief Medical Officer --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-23 Keli Walbert Director Other Derivative Acquisition +36,000 $35.72
2026-06-15 RA Capital Management, L.P. -- Open Market Acquisition +67,669 $24.89–24.98
2026-05-19 RA Capital Management, L.P. -- Open Market Acquisition +4,798 $24.94–24.97
2026-05-11 RA Capital Management, L.P. -- Open Market Acquisition +6,387 $24.90
2026-05-10 RA Capital Management, L.P. -- Open Market Acquisition +51,258 $24.34–25.00
2026-05-05 RA Capital Management, L.P. -- Open Market Acquisition +165,429 $23.77–25.00
2026-05-03 John Michael Maraganore Independent Chairperson Derivative Exercise and Retained +35,948 --
2026-05-03 Novo Holdings A/S -- Derivative Exercise and Retained +4,180,550 --
2026-05-03 RA Capital Management, L.P. -- Private Acquisition +2,675,000 $18.00
2026-05-03 RA Capital Management, L.P. -- Derivative Exercise and Retained +4,838,086 --
2026-05-03 Access Biotechnology -- Initial Statement of Beneficial 0 --
2026-04-29 John Michael Maraganore Independent Chairperson Initial Statement of Beneficial 0 --
2026-04-29 Novo Holdings A/S -- Initial Statement of Beneficial 0 --
2026-04-29 Akshay Vaishnaw Independent Director Initial Statement of Beneficial 0 --
2026-04-29 Linda Bain Independent Director Initial Statement of Beneficial 0 --
2026-04-29 Benny Sorensen Chief Executive Officer Initial Statement of Beneficial 0 --
2026-04-29 Catherine Madigan Chief Medical Officer Other Derivative Acquisition +49,016 $18.00
2026-04-29 Catherine Madigan Chief Medical Officer Initial Statement of Beneficial 0 --
2026-04-29 Mads Behrndt-Eriksen CFO & GM Other Derivative Acquisition +49,016 $18.00
2026-04-29 Mads Behrndt-Eriksen CFO & GM Initial Statement of Beneficial 0 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Hemab Therapeutics Holdings discussion 0 comments

Add a comment